Alkem Laboratories has posted satisfactory financial performance during the third quarter ended December 2015. Its consolidated net profit increased by 17 per cent to Rs.188.93 crore from Rs.161.48 crore and EBIDTA by 27.8 per cent to Rs.268.42 crore from Rs.210.07 crore in the corresponding period of last year. The company’s net sales increased by 28.6 per cent to Rs.1,246 crore from Rs.969 crore.
Alkem has completed its initial public offering of 128.53 lakh shares of Rs.2 each for cash at a price of Rs.1,050 per equity share through an offer for sale. The public issue was oversubscribed by over 44 times. Its equity capital now stood at Rs.23.91 crore. Alkem share gained Rs.41.75 today, after announcement of financial results, to Rs.1319 on BSE. EPS for face value of Rs.2 each share improved to Rs.15.8 from Rs.13.5 in the last period.
Alkem’s pharma business improved by 29 per cent to Rs.1,275 crore from Rs.988 crore in the similar period of last year. Its revenues in India increased by 21.3 per cent to Rs 893 crore from Rs.736 crore contributing 71.7 per cent to its total revenues. Its exports improved to Rs.415 crore from Rs.288 crore, a strong growth of over 44 per cent.
For the nine months ended December 2015, Alkem’s consolidated net sales improved by 36 per cent to Rs.3,766 crore from Rs.2,768 crore in the same period of last year. Its net profit has taken quantum jump of 137 per cent and touched to Rs.616 crore from Rs.260 crore. EBIDTA moved up by 94.4 per cent to Rs.812.11 crore from Rs.417.73 crore